The deal gives Genzyme shareholders individual contingent evaluate real on behalf of every one share owned. These CVRs cause holders the decent to coins payments based on Genzyme engagement firm goals, plus raising production levels pro Cerezyme and Fabrazyme, getting final FDA endorsement pro multiple sclerosis therapy Lemtrada, and advanced sales targets.Genzyme says it expects three new-fangled invention approvals by the outcome of 2013. persons are Lemtrada, a new-found Gauchers disease behavior called eliglustat, and mipomersen, which is a behavior domestic hypercholesterolemia, a genetic disorder to causes towering cholesterol levels.Genzyme as well reported its fourth-quarter results Wednesday. The company understood its profit climbed to $471.